Skip to content

Optimer

How robust are Optimer-based affinity columns?

As part of the recent Biologics Europe 2021 digital conference our CTO, Dr David Bunka, was invited to present as part of Sartorius’ workshop in the ‘Protein Engineering, Protein…

Aptamer-enhanced gene therapy delivery

Gene therapy is the future for the treatment of several, often life-threatening conditions. Several gene therapy assets are currently under trial targeting cancers, sensory organs, blood disease, and rare…

New methods for hapten bioanalysis

Anti-hapten antibodies are difficult and slow to generate limiting cheap and efficient bioanalysis in this field. Our proprietary methods offer standard assay formats, such as ELISA and lateral flow…

Aptamer intellectual property and licensing

Aptamers function as chemical antibodies across a range of applications. From quality control reagents to point-of-care diagnostics and clinically relevant therapeutics, regardless of the end-use of the developed reagent,…

Anti-hapten antibody production problems

Why are haptens such a hard-to-solve target class for antibody development? Small molecules are ubiquitous in our environment. They cover hormones and toxins to drugs and vitamins. There is an…